Alnylam Pharmaceuticals
ALNY
#638
Rank
NZ$54.74 B
Marketcap
$421.91
Share price
-0.59%
Change (1 day)
40.62%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$6.55

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$7.11. In 2022 the company made an earnings per share (EPS) of -$16.06 a decrease over its 2021 EPS that were of -$12.45.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$6.55-59.2%
2022-$16.0629.03%
2021-$12.45-3.36%
2020-$12.88-8.48%
2019-$14.087.67%
2018-$13.0739.74%
2017-$9.3512.94%
2016-$8.2838.84%
2015-$5.97-32.88%
2014-$8.89259.44%
2013-$2.47-31.25%
2012-$3.6052.94%
2011-$2.3530.77%
2010-$1.80-8.77%
2009-$1.9778.13%
2008-$1.11-70.78%
2007-$3.7999.09%
2006-$1.90-43.88%
2005-$3.39-82.33%
2004-$19.18-59.23%
2003-$47.05

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.94-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$64.60-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$13.54 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.47-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.92-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.47-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$5.50-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$3.46-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel